Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study

Sulfatinib is a small molecule kinase inhibitor that targets tumor angiogenesis and immune modulation. This phase I study (NCT02133157) investigated the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of sulfatinib in patients with advanced solid tumors. The study includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jian Ming, Wang, Yan, Chen, Yu Ling, Jia, Ru, Li, Jie, Gong, Ji Fang, Li, Jing, Qi, Chuan, Hua, Ye, Tan, Cui Rong, Wang, Jian, Li, Ke, Sai, Yang, Zhou, Feng, Ren, Yong Xin, Qing, Wei Guo, Jia, Hong, Su, Wei Guo, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522050/
https://www.ncbi.nlm.nih.gov/pubmed/28159938
http://dx.doi.org/10.18632/oncotarget.14942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522050/
https://www.ncbi.nlm.nih.gov/pubmed/28159938
http://dx.doi.org/10.18632/oncotarget.14942

Ejemplares similares